Lunit's AI Breakthrough: Predicting EGFR Mutations in Lung Cancer from Standard Scans

Lunit's AI can spot EGFR mutations from a regular scan

Lunit will present an AI study on predicting EGFR mutations in non-small cell lung cancer (NSCLC) at the American Association for Cancer Research (AACR) Annual Meeting 2025, held from April 25 to 30 in Chicago, Illinois. The study, conducted with AstraZeneca, unveils the Lunit SCOPE Genotype Predictor, an AI model that predicts EGFR mutations from standard H&E-stained tissue samples. The Lunit SCOPE Genotype Predictor stands out for its robust performance in diverse clinical settings. Its capabilities hinge on an extensive and varied dataset, which includes over 12,000 pathology slides sourced from patients across multiple countries, ensuring its real-world applicability. Predicting EGFR mutations is vital for identifying effective treatment pathways. Then, ensuring widespread and accurate testing remains challenging due to logistical and resource constraints within clinical environments. The dataset comprises over 4,500 EGFR-mutated slides and more than 7,500 wild-type slides from different geographic regions, reinforcing the model's versatility. Performance remained consistent across various clinical variables: The tool shows potential as a cost-effective and rapid method to ensure timely diagnosis. Verbatim reported comments from Brandon Suh, CEO of Lunit, on study findings include how validating routine pathology slides for predicting driver mutations mitigates delays in targeted therapy. Case Status just turned law firms into time-travelling mind readers Lunit has established a strong global footprint over the past decade. Founded in 2013 in Seoul, South Korea, Lunit is a leading provider of AI-powered cancer diagnostics and therapeutic solutions. Their Lunit INSIGHT suite, FDA-cleared for cancer screening, is in use across over 4,800 medical institutions in 55 countries. Collaborative clinical studies from Lunit appear in journals including the Journal of Clinical Oncology and the Lancet Digital Health. Its research presentations extend to high-impact conferences like ASCO and RSNA. With a diverse and extensive international reach headquartered in South Korea, Lunit's impact on cancer research and treatment is still growing. The real kicker here is not just the promise of AI in cancer diagnostics but the hard-nosed execution: training on a mind-boggling 12,000 pathology slides from multiple countries, ensuring it's ready for the messy realities of global medicine. Lunit's deployment of AI is a giant leap from the limited, controlled environments where diagnostic tools often falter; solidifying diverse datasets and consistent performance across different clinical settings.

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca By Investing.com

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC SEOUL, South Korea, March 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, will present a deep learning study on Epidermal Growth Factor Receptor (EGFR) mutation prediction in patients with non-small cell lung cancer (NSCLC) at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, held from April 25 to 30 in Chicago, Illinois. The study, which highlights the development and validation of the Lunit SCOPE Genotype Predictor, an AI-powered deep learning model capable of predicting EGFR mutations directly from hematoxylin and eosin (H&E)-stained tissue samples in NSCLC patients, will be presented in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN). EGFR mutation testing plays a crucial role in determining the best course of treatment for patients with NSCLC, yet many patients remain untested due to logistical and resource constraints, despite guideline recommendations. Existing AI models designed to predict mutations from pathology images have faced limitations in real-world clinical applications due to limited training data and lack of validation. Lunit and AstraZeneca's collaborative study leveraged the largest and most diverse training dataset to date, consisting of more than 12,000 pathology slides (>4,500 EGFR-mutated and >7,500 wild-type) from NSCLC patients across multiple countries, including the US, China, and South Korea, to further develop and validate Lunit's model. The AI model's performance remained consistent across key clinical variables including specimen types, EGFR mutation subtypes, slide scanners, and scan magnifications, reinforcing its potential for real-world deployment in diverse clinical environments. The collaboration focuses on the development of the Lunit SCOPE Genotype Predictor, an AI-driven tool designed to rapidly and cost-effectively predict NSCLC driver mutations from H&E-stained tissue samples. "This study is a testament to the real-world potential of AI in precision oncology," said Brandon Suh, CEO of Lunit. "By leveraging Lunit AI, we have demonstrated that routine pathology slides can serve as a powerful tool to predict EGFR mutations with high accuracy. This could help clinicians prioritize molecular testing for NSCLC patients, ensuring that patients receive targeted therapy without unnecessary delays. We are excited to showcase this breakthrough at AACR 2025, reinforcing our commitment to advancing AI-driven precision oncology in collaboration with AstraZeneca." Join Us at AACR 2025 Founded in 2013, Lunit (KRX:328130.KQ) is a medical AI company on a mission to conquer cancer through AI. Lunit harnesses AI-powered medical image analytics and biomarker analysis to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,800 medical institutions across 55+ countries. Lunit clinical studies have been published in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer. Discover more at lunit.io.